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AP-1 activating protein-1
ARMD age-related macular degeneration
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α2M α2-macroglobulin
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bFGF basic fibroblast growth factor
BSA bovine serum albumin
DMBA 7,12-dimethylbenzantracene
EGF epidermal growth factor
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HCE16/3 human cervical epithelial cells (HPV-16 virus-transformed)
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MMP matrix metalloproteinase
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NHBE normal human bronchial epithelial cells
NMDA N-methyl-D-aspartate
NMDAR N-methyl-D-aspartate receptor
PA plasminogen activation
PAI-1 plasminogen activator inhibitor-1
PAI-2 plasminogen activator inhibitor-2
PDGF platelet-derived growth factor
PEA3 polyomavirus enhancer A-binding protein-3
PMA 12-tetradecanoylphorbol-13-acetate
9PVR proliferative vitreoretinopathy
RA retinoic acid
RD rhabdomyosarcoma cells
RPE retinal pigment epithelium
SDS sodium dodecyl sulfate
SMC smooth muscle cell
suPAR soluble urokinase receptor plasminogen activator
T3 triiodothyronine
TGF-β transforming growth factor-β
TIMP tissue inhibitor of matrix metalloproteinase
tPA tissue plasminogen activator
TRITC tetramethyl rhodamine isothiocyanate
uPA urokinase plasminogen activator
uPAR urokinase plasminogen activator receptor
VEGF vascular endothelial growth factor
VN vitronectin
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ABSTRACT
The main components of plasminogen activation include plasminogen, tissue
plasminogen activator (tPA), urokinase plasminogen activator (uPA), urokinase
plasminogen activator receptor (uPAR), and plasminogen activator inhibitors-1 and -2
(PAI-1, PAI-2 ).
uPA and its receptor uPAR are known to be important in cell migration/adhesion. In
these studies, we show that uPAR was anchored in focal contacts in a uPA-dependent
manner, whereas in its unoccupied form uPAR appeared diffusely on the cell surface.
Moreover, αvβ3-integrin was found in close proximity to uPAR in the focal contacts.
We also studied the effect of transforming growth factor-β (TGF-β) and interferon γ
(IFN-γ) retinal pigment epithelial cells (RPE) and observed that TGF-β increased uPAR
expression.
tPA has been considered to be mainly a fibrinolytic enzyme. We observed that in
human uterine cervical epithelial cells immortalized with HPV-16 (human
papillomavirus type 16) DNA, the tPA activity levels were very low or even
undetectable due to an inhibitory effect of hydrocortisone in the growth medium.
Withdrawal of hydrocortisone increased tPA mRNA expression, which seemed to be a
later event than uPA mRNA expression. tPA activity levels increased dramatically at 72
hours when hydrocortisone was eliminated from the growth medium. Elimination of
hydrocortisone also increased tPA and uPA activity levels in two other nonmalignant
human epithelial cells.
Based on results from in vitro observations, the presence of tPA was examined in
normal, precancerous, and malignant epithelial tissue lesions by
immunohistochemistry. In addition, in situ hybridization was used to demostrate tPA
mRNA expression. Immunohistochemistry revealed that tPA was expressed at high
levels in normal, condylomatous, and dysplastic squamous epithelium. Expression of
tPA mRNA was restricted to the proliferating basal and parabasal cell layers, whereas
tPA protein synthesis became evident in the next cell layers. tPA immunostaining in
cancer cells was mostly negative or weak in adenocarcinoma and strong in epidermoid
carcinoma. We detected tPA mRNA in adenocarcinoma but not in epidermoid
carcinoma. In epidermoid carcinoma, the surrounding stromal cells were positive.
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REVIEW OF THE LITERATURE
PLASMINOGEN ACTIVATION
Serine proteinases belong to a family of proteinases that hydrolyze peptide bonds in
proteins. They contain the amino acid serine in their active center. Enzymes of the
plasminogen activator cascade also belong to this family. The end product of the
plasminogen activation cascade is plasmin, a proteolytic enzyme with a broad substrate
affinity. Historically, plasminogen, plasmin, and plasminogen activators have been
associated with fibrinolysis (Astrup, 1966; Christman et al., 1977; Danø, 1985). Already
in the early 1890s, fibrin was known to be digested and not dissolved in blood
(Macfarlane and Biggs, 1948). In 1933, Tillett and Garner demonstrated that hemolytic
streptococcal broth could dissolve a normal human fibrin clot. The active factor
originating from the streptococcal broth was called fibrinolysin. Later, Milstone (1941)
noticed that when the fibrin preparation was sufficiently pure, fibrinolysis failed to
occur or occurred very slowly. However, addition of the human serum euglobulin
fraction once again enabled fibrinolysis. Milstone revealed that human serum contains a
”lytic factor”, and this lytic factor together with bacterial fibrinolysin could lyse fibrin
clots. Christensen (1945) and Christensen and Macleod (1945) discovered that the lytic
factor and serum proteinase are one and the same enzyme occurring in a precursor
form and that both can be activated by fibrinolysin. They demonstrated that fibrinolysis
is a proteolytic activity and that this enzyme was capable of cleaving fibrin, fibrinogen,
casein, and gelatin. They suggested a revised nomenclature to avoid confusion with
other proteinases in the blood/serum. The serum proteinase and the active form of the
lytic factor were named plasmin, and the precursor form was called plasminogen.
Streptococcal fibrinolysin they named streptokinase (Christensen, 1945; Christensen
and MacLeod, 1945; Astrup and Permin, 1948).
How does plasminogen activation occur? Animal tissues were found to contain a
fibrinolytic activator (Astrup and Permin, 1947) which could “transform”
profibrinolysin (plasminogen) into fibrinolysin (plasmin). In the 1947 scheme, this
transformation was shown to occur spontaneously, following the treatment of serum
with chloroform, streptokinase, or tissue activator. A major obstacle was that these
activators could not be purified, since, for example, tissue activator had a strong
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adherence (affinity) to cellular components, hindering the purification process.
Although fibrin-cleaving activity was detected in urine nearly 100 years ago (Astrup,
1956), the identification took place many decades later. This substance was called
urokinase since it was isolated from human and dog urine (Williams, 1951; Astrup and
Sterndorff, 1952; Sobel et al., 1952). Plasminogen activator from urine and blood was
added to the scheme of plasminogen activation, and trypsin was also shown to activate
plasminogen (Astrup, 1956). The mechanism of conversion of plasminogen to plasmin
was discovered by Robbins et al. in 1967.
CONTRIBUTING FACTORS IN PLASMINOGEN ACTIVATION
Plasminogen
Plasminogen is a single-chain glycoprotein with a molecular weight of
approximately 92 kDa. Plasminogen is synthesized mainly in the liver (Raum et al.,
1980), and this inactive form circulates in the vasculature but is also found ubiquitously
in all body fluids. Secreted plasminogen is a precursor that is cleaved by plasminogen
activators at a single site, the Agr561-Val562 bond (Robbins et al., 1967; Petersen et al.,
1990), to yield a two-chain plasmin held together by two disulfide bonds (Sottrup-
Jensen et al., 1978). The structural features of the plasminogen molecule include an N-
terminal (A-chain) component, which has a pre-activation peptide (from 1-77), followed
by five tandem structures called kringle domains. Kringle domains participate in
binding to fibrin and to the cell surface (Ponting et al., 1992). In its B-chain (carboxyl-
terminal region) lies the catalytic domain with the His-Asp-Ser characteristic triad of
serine proteinases (Petersen et al., 1990; Parry et al., 2000).
The proenzyme plasminogen exists in the circulation with Glu (glutamic acid) amino
acid in its NH2-terminus, and cleavage of the N-terminal peptide produces Lys-terminal
plasminogen, which is more easily activated by plasminogen activators (Fig. 1).
Removal of the terminal Glu is not, however, a prerequisite for the activation of
plasminogen. The N-terminal peptide is probably needed for the regulation of a
conformational change and for the activation properties of the native molecule (Ponting
et al., 1992). Plasminogen can also be cleaved with trypsin to activate it to plasmin and
with elastase. Elastase cleavage of plasminogen yields two fragments: angiostatin
including kringles 1-4 and miniplasmin consisting of the serine protease domain and
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kringle 5 (Parry et al., 2000) (Fig. 1). Angiostatin has been shown to inhibit angiogenesis
(Pepper, 2001).
Tissue plasminogen activator (tPA)
The mRNA for tPA is approximately 2.7 kb and encodes a glycoprotein with a
molecular weight of about 70 kDa (Pennica et al., 1983; Fisher et al., 1985). tPA protein is
secreted as a single-chain glycoprotein. Similarly to uPA, tPA can be cleaved by plasmin
to a two-chain form held together by a single disulfide bond (Table 1). The tertiary
structure of tPA differs from that of uPA. The N-terminal (A-chain or heavy-chain)
region has a finger domain followed by a growth factor domain, and two kringle
domains. The carboxyl-terminal (B-chain or light-chain) region contains a serine
protease domain (Ny et al., 1984). Unlike uPA, single-chain tPA has significant activity
(Tachias and Madison, 1996). Binding of tPA to fibrin enhances plasminogen activation
markedly. The finger domain and kringle domain are important in binding of tPA to
fibrin (Collen, 1999). Endothelial cells in particular produce tPA (Levin and del Zoppo,
1994; Levin et al., 1997), as do human keratinocytes, melanocytes, and neurons (Chen et
al., 1993; Bizik et al., 1996; Teesalu et al., 2002). Of neoplastic cells, tPA can be produced
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Figure 1. Schematic diacram of plasminogen and its cleavage products.
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by melanoma, neuroblastoma, ovarian cancer, breast cancer, and pancreatic cancer cells
(Rijken and Collen, 1981; Amin et al., 1987; Neuman et al., 1989; Paciucci et al., 1998).
Urokinase plasminogen activator (uPA)
The urokinase mRNA of 2.5 kb (Verde et al., 1984) encodes a single-chain
glycoprotein with a molecular weight of 53 kDa (Lesuk et al., 1965; Wun et al., 1982a,
1982b). The enzyme is activated by cleavage of a single peptide bond. This cleavage can
be catalyzed by plasmin, for example (Wun et al., 1982b; Collen et al., 1986; Tapiovaara
et al., 1993). Active urokinase is a two-chain form held together by a single disulfide
bond (Table 1). The tertiary structure of uPA is composed of three different domains.
The N-terminal A-chain (light chain) includes a growth factor domain followed by one
kringle domain (Blasi et al., 1987, 1988). These together are known as the amino-terminal
fragment (ATF) (1-135 amino acids) (Stoppelli et al., 1985). The receptor-binding site has
been mapped to the growth factor domain of the ATF-fragment (Appella et al., 1987). In
the carboxyl-terminal region, also known as B-chain (heavy chain), uPA has a serine
protease domain. The two chains are linked with a connecting peptide (tPA does not
have it). Active two-chain uPA is also referred to as high molecular weight (HMW)
urokinase. Additional cleavage between amino acids 134-135 separates the light chain
(ATF-fragment) and the heavy chain containing the active serine protease domain. This
cleavage has also been shown to occur with plasmin (Blasi et al., 1987, 1988). Urokinase
is secreted by many types of cancer cells, including breast, colon, ovary, gastric, cervix,
endometrium, bladder, kidney, and brain tumor tissues, in higher amounts than by the
corresponding normal tissues (Andreasen et al., 1997). While the cells producing uPA in
cancer tissue remain unidentified, in colon carcinoma urokinase has been established to
be secreted mainly by the cancer cells themselves (Berger, 2002).
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Table 1. Structural features of tPA and uPA.
tPA uPA
mRNA 2.7 kb 2.5 kb
molecular weight 70 kDa 53 kDa
finger domain growth factor domain
A-chain growth factor domain one kringle
two kringles (ATF-fragment,
(heavy chain) light chain)
B-chain protease domain protease domain
(light chain) (heavy chain)
connecting peptide not included included
zymogenity low high
Receptors for plasminogen activators
Cell membrane-bound high-affinity receptors for tissue plasminogen activator have
not been identified. Yet, tPA binds to many proteins, and fibrin is by far the most
efficient binding protein. In at least one respect, fibrin can be said to act as a receptor for
tPA; in the presence of fibrin, tPA-catalyzed plasminogen activation occurs at least 100-
fold more effectively than in its absence (Hoylaerts et al., 1982; Collen, 1999). If not a
true receptor, it is at least a cofactor for tPA. Other tPA candidate receptors include
mannose-6-phosphate/IGF II receptor, annexin II, and amphoterin (Otter et al., 1991;
Parkkinen and Rauvala, 1991; Hajjar et al., 1994). In addition, tPA binds to extracellular
matrix components such as laminin and fibronectin (Salonen et al., 1984, 1985).
uPA has high-affinity binding sites on the cell surface (Stoppelli et al., 1985, 1986
Vassalli et al., 1985). Urokinase plasminogen activator receptor (uPAR), originally
purified from several different cell lines, has a molecular weight of approximately 55
kDa (Nielsen, 1988). The receptor showed specific binding of urokinase and the
urokinase ATF-fragment. The mRNA for uPAR is 1.4 kb (Roldan et al., 1990). Binding of
uPA to its receptor is species-specific, i.e. human uPA does not bind to murine uPAR
and murine uPA does not bind to human uPAR (Estreicher et al., 1989). Fully processed
uPAR is heavily glycosylated (Behrendt et al., 1990). In its carboxyl-terminal region,
uPAR has a glycosyl-phosphatidylinositol moiety (GPI-anchor) by which uPAR is
integrated into the outer leaflet of the cell membrane (Ploug et al., 1991). The tertiary
structure of uPAR is formed by three homologous repeats known as domains 1, 2, and 3
(D1, D2, D3) (Behrendt et al., 1991; Ploug et al., 1993). Based on its protein structure,
uPAR belongs to the glycolipid-anchored Ly-6 superfamily of proteins (Ploug and Ellis,
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1994). The ligand-binding site is located in domain 1 (D1), which is also the first repeat
starting from the amino-terminus (Behrendt et al., 1991). Purified or cell membrane-
bound uPAR is cleaved either partially or totally (Behrendt et al., 1991; Ploug et al., 1991;
Høyer-Hansen et al., 1992), and it therefore exists in soluble form. High levels of soluble
uPAR (suPAR) can be measured, for example, in patients with acute myeloid leukemia
(Mustjoki et al., 2000). uPAR is expressed at elevated levels in breast colon, gastric, and
certain lung carcinoma tissues (Andreasen et al., 1997). Disagreement exist between
different laboratories as to which cells produce uPAR, whether it is produced by stromal
cells such as macrophages or by cancer cells in breast and colon carcinomas tissues
(Mazar, 2001).
Plasminogen activator inhibitors
PAI-1 and PAI-2
The two known physiological inhibitors for uPA and tPA are plasminogen activator
inhibitors-1 and -2 (PAI-1 and PAI-2, respectively). PAI-1 and PAI-2 belong to the gene
family of serine protease inhibitors called serpins (Ny et al., 1986; Antalis et al., 1988;k
Ye et al., 1989). Both are glycoproteins. The molecular weight of PAI-1 is about 54 kDa
(Andreasen et al., 1986a). PAI-1 has two mRNAs (2.4 and 3.2 kb), which is thought to be
due to alternative polyadenylation sites. Serpins can adopt a variety of conformations
under physiological conditions. PAI-1 can exist in its native inhibitory form, in an
inactive, latent form, in complexes with proteinases, and in a cleaved substrate form
(Lawrence, 1997, 2000). In addition, PAI-1 can form complexes with vitronectin, while
simultaneously retaining its activity (Salonen et al., 1989). Cultured endothelial cells as
well as many other cultured cells secrete PAI-1 (Hekman and Loskutoff, 1985). In the
fibrosarcoma cell line HT-1080 (Nielsen et al., 1986), PAI-1 is also bound to the
substratum of the cells (Pöllänen et al., 1987). PAI-1 is the major inhibitor of tPA in
circulation. Platelets contain a large pool of PAI-1, mostly in an inactive form
(Andreasen et al., 1990).
PAI-1 forms complexes both with single-chain and two-chain tPA and with two-chain
uPA (Andreasen et al., 1986b). However, PAI-1 has also been shown to form a reversible
complex with single-chain uPA (Manchanda and Schwartz, 1995). Receptor-bound
active urokinase is inhibited by PAI-1 and PAI-2 (Cubellis, 1989; Stephens et al., 1989;
Ellis et al., 1990), which leads to the inhibition of plasminogen activation.
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Based on the amino acid and gene structure, PAI-2 belongs to a subgroup of the
serpin superfamily, ovalbumin-type serpins (Ye et al., 1989; Silverman et al., 2001). Its
gene is transcribed to a 2.0-kb mRNA (Ye et al., 1989). PAI-2 protein exists in two forms:
in a nonglycosylated intracellular form and in a glycosylated, secreted extracellular form
(Belin, 1992). PAI-2 can also be detected as a polymer intracellularly (Mikus and Ny,
1996). The molecular weight of the intracellular form is about 42 kDa and that of the
secreted form 60 kDa. PAI-2 inhibits uPA rapidly, but tPA very slowly (Andreasen et al.,
1990). PAI-2 is expressed as an inflammatory response in macrophages and also in
keratinocytes under certain conditions (Belin, 1992; Chen et al., 1993).
α2-antiplasmin and α2-macroglobulin
The serpin inhibitor α2-antiplasmin is the primary inhibitor of plasmin (Wiman and
Collen, 1978). It forms a complex with plasmin by occupying the plasmin kringle
domains, i.e. the lysine-binding sites. It is a fast inhibitor of free plasmin in circulation
and in solution. When plasmin/plasminogen is bound to the cell surface, its lysine-
binding sites are occupied, and therefore, α2-antiplasmin acts more slowly (Ponting et
al., 1992).
 α2-macroglobulin is found in circulation in vast quantities (Sottrup-Jensen, 1989) It is
a large glycoprotein which can trap proteinases and their inhibitor complexes. α2-
macroglobulin complexes are internalized by means of low-density lipoprotein-related
receptor (LRP) (Borth, 1992). α2-macroglobulin binds plasminogen activators and their
inhibitor complexes as well as plasmin. Cell-bound plasmin is protected from α2-
macroglobulin.
PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL ROLES OF PLASMINOGEN
ACTIVATION
Despite uPA and tPA being impressively similar in structure and having common
inhibitors and physiological substrates, their physiological roles are quite distinct.
Traditionally, the role of tPA has been as a mediator of fibrinolysis in vasculature
(Lijnen and Collen, 1991; Collen, 1999). Urokinase is strongly linked to cell migration,
especially in cancer cells (Andreasen et al., 1997). Thus far, more than one target for
tPA/plasmin has been found in neuronal tissues (Chen and Strikland, 1997; Wu et al.,
2000; Traynelis and Lipton, 2001). The functional role of the PAIs is no longer simply to
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inhibit overexpressed plasminogen activators; PAI-1 also participates in cell adhesion
via the adhesion protein vitronectin (Loskutoff et al., 1999) and in angiogenesis (Bajou et
al., 1998), and PAI-2 has an unidentified role in the regulation of cell death (Silverman et
al., 2001).
Factors influencing plasminogen activation
Consequences of plasminogen activation
The discovery that plasmin solubilizes the fibrin network after its polymerization led
to the utilization of plasminogen activators as thrombolytic agents in cardiovascular
diseases and ischemic stroke (Lijnen and Collen, 1991; Collen, 1999). In knock-out mice
studies, plasminogen and its activators deficiency has been demonstrated to cause
severe thrombosis (Carmeliet et al., 1994; Bugge et al., 1995). uPAR-uPA participate in
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Figure 2. Factors influencing  increasing and decreasing expression of
plasminogen activation (PA) components. Structural defects of PA components
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fibrinolysis, but extravascularly (Idell, 2002). Plasmin is necessary in wound healing
(Bugge et al., 1996; Rømer et al., 1996) and matrix metalloproteinases (MMPs) are
needed to complete the wound healing process (Lund et al., 1999).
In physiological or pathophysiological conditions, PA and MMPs act in concert.
Proteolytic processing of the structural hemidesmosome protein laminin-5 is an example
of one such target protein. Recent in vitro studies have addressed plasmin and tPA
regulating the proteolytic processing of the α3-chain of laminin-5, which results in the
assembly of stabilized hemidesmosome structures and cessation of cell migration
(Goldfinger et al., 1998). The same group demonstrated that uPA, plasmin, and integrin
ligation with uPAR was involved in the processing of the laminin-5 α3-chain, thus
reducing cell motility (Ghosh et al., 2000). Cleavage of the laminin-5 γ2-chain by MMP-2
induces cell migration (Giannelli et al., 1997), although MT1-MMP was later shown to be
mainly responsible for the truncated form of the laminin-5 γ2-chain with or without
MMP-2 (Koshikawa et al., 2000). Interestingly, uPAR and the truncated form of the
laminin-5 γ2-chain are coexpressed in colon adenocarcinomas in front of invasive cancer
cell islands (Pyke et al., 1995). Moreover, the overexpression of uPA and uPAR
(bitransgenic mouse) in basal mouse keratinocytes increased plasminogen activation
and cooperated in pathogenic proteolysis, which led to the partly disruption of
hemidesmosomes and epidermal blistering (Zhou et al., 2000). In the same study, MMP-
9 and MMP-2 were shown to be activated only in bitransgenic mice. However, the
proteolytic conversion of plasminogen to plasmin can occur without uPAR (Carmeliet et
al., 1998). Plasmin can activate several matrix metalloproteinases in vivo; for example,
during aneurysm formation MMP-3, -9, -12, and -13 are activated (Carmeliet et al., 1997).
uPA-uPAR complex formation on the cell surface has proteolytic, cell migratory,
adhesive, and more recently characterized chemotactic effects. The cleavage of uPAR
between domain 1 (D1) and domain 2 (D2) exposes an epitope fragment on the side of
D2D3 uPAR which is chemotactic (Fazioli et al., 1997). The binding of uPA to uPAR
seems to be needed to unmask the chemotactic uPAR sequence. Whether the cleavage
occurs by uPA or other proteinases in vivo remains to be seen (Fazioli et al., 1997;
Koolwijk et al., 2001). It is not clear whether the D2D3 soluble form, the membrane-
attached form, or both induce the chemotactic effect in vivo (Blasi and Carmeliet, 2002).
The D2D3 sequence of uPAR interacts with the chemotactic formyl peptide receptor
(FPR)/FPR-like receptor-1 (FPRL1) (Resnati et al., 2002). The presence of the two
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activators in the joints of rheumatoid arthritis patients seems to have opposing effects on
disease severity: tPA has a protective role and uPA is deleterious (Yang et al., 2001;
Cook et al., 2002). This is possibly based on tPA-mediated fibrin clearance and uPA-
mediated recruitment of inflammatory cells and cytokines in arthritic joints.
Plasmin has the capacity to release and activate growth factors, hormones, and
proteases such as transforming growth factor-β (TGF-β) (Lyons et al., 1990; Taipale et al.,
1992), fibroblast growth factor (FGF) (Saksela and Rifkin, 1990), insulin-like growth
factor-binding protein-4 (IGFBP-4) (Remacle-Bonnet et al., 1997), and latent collagenases
(O'Grady et al., 1981; Mazzieri et al., 1997). In vitro, plasmin converts proinsulin,
adrenocorticotrophin (ACTH) (Granelli-Piperno and Reich, 1983), and interleukin-1β
(IL-1β) (Matsushima et al., 1986) in their active forms. In addition, uPA has been shown
to activate hepatocyte growth factor (HGF) in vitro (Naldini et al., 1995). Plasmin can
also activate latent TGF-β in a reaction where uPAR facilitates this activation on the cell
surface via bound uPA (Odekon et al., 1994).
The plasminogen activation system is involved in pathological conditions of the
human eye. Retinal pigment epithelium (RPE) is composed of a single layer of cells
between the retina and the choroid. Photoreceptors (rods and cones) of the retina are in
contact with RPE. Bruch's membrane underlies the RPE. Thickening of Bruch's
membrane is an early clinical sign of age-related macular degeneration (ARMD)
(Ruberti et al., 2003), a severe form of which is choroidal neovascularization (CNV). In
eye diseases such as ARMD and proliferative vitreoretinopathy (PVR) detachment of
retinal pigment epithelial cells and their migration can occur (Glaser and Lemor, 1989;
Elner, 2002). RPE cells secrete uPA and PAI-1 (Sirén et al., 1992). Retinal glial and retinal
endothelial cells have also been shown to secrete tPA (Wileman et al., 2000; Schacke et
al., 2002). Migration of RPE cells occurs in an uPAR-PAI-1 dependent manner (Elner,
2002). It is also noteworthy that the MMP inhibitor TIMP3 and PAI-1 have opposite
effects on choroidal neovascularization; TIMP3 inhibits angiogenesis by blocking
vascular endothelial growth factor (VEGF) from binding to its receptor (Qi et al., 2003)
and PAI-1 enhances angiogenesis (Lambert et al., 2001).
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Plasminogen activation and tumorigenesis
The connection between increased fibrinolytic activity and cancer was initially
described more than 80 years ago. The pioneers Alex Carrel and Albert Fischer, among
others, discovered that cancer cells continuously dissolve plasma clots in culture by
proteolytic digestion (Danø, 1985). In the 1970s, the evidence was strengthened by
plasminogen activators being produced in higher amounts in transformed cell lines
(Unkeless et al., 1974). Plasminogen activation has been firmly linked to cancer cell
invasion. Plasmin with its degrading capacity has been thought to facilitate tumor cells
passage through barriers, such as basement membranes and interstitial connective
tissue, and migration to distant body sites. The invasion of cancer cells is associated with
the secretion of high amounts of uPA (Andreasen et al., 1997). An elevated level of uPA
correlates with malignancy (Duffy, 2002). This has also been shown in the reverse.
Human epidermoid carcinoma cells lose their malignant behavior if they are cultured
for a prolonged time. This is accompanied by a number of changes, including reduced
uPA synthesis (Ossowski and Belin, 1985). High levels of uPA and uPAR are related to
poor prognosis, and it therefore came as a surprise that high PAI-1 levels are also a
marker for negative prognosis in certain cancers (Schmitt et al., 1997).
Cancer cells have an enormous capacity to migrate. The mechanism, by which
plasminogen activation facilitates cancer cell migration has been thought to be
proteolysis of extracellular matrice alone. Recently, it has become clear that the situation
is much more complex and that alternative routes exist within the plasminogen
activation system. The components of the plasminogen activation cascade, namely uPA,
uPAR, and PAI-1, take part in cell adhesion and migration. This function is partly
independent of the proteolytic or inhibitory functions of the PA components. The first
suggestion that PAI-1 plays a role in cell adhesion came from Ciambrone and
McKeown-Longo (1990), who demonstrated that PAI-1 can disturb the interaction
between vitronectin and its receptor. More recently, uPAR has been discovered to be a
ligand for integrins (Tarui et al., 2001). In addition, PAI-1-channelled cell detachment is
mediated by endocytosis of the uPA-uPAR-PAI-1-integrin complex (Czekay et al., 2003).
As already mentioned, High levels of uPA and unexpectedly PAI-1 are associated
with poor prognosis in many cancers, including breast cancer (Schmitt et al., 1997;
Duffy, 2002). The role of PAI-1 in cancer cells is unclear. It might be related to
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angiogenesis in which PAI-1 seems to be involved. Alternatively it may be due to either
the protease-inhibitory or the adhesive function of PAI-1 or both (Bajou et al., 2001;
McMahon et al., 2001). Both the protease-inhibitory and the adhesive function via
vitronectin/integrin participate in regulation of cancer metastasis (Praus et al., 2002).
Role of tPA in the brain
In 1981, tPA was demonstrated to be released at the neuronal growth cone (Krystosek
and Seeds, 1981). The morphological differentiation of neuroblastoma cells was
accompanied by tPA induction, also suggested to have a role in neuronal cell functions
(Neuman et al., 1989). Involvement of plasmin(ogen) as well as tPA in brain function has
been studied in knock-out mice. tPA participates in neuronal plasticity such as
involvement in memory and learning activities (Madani et al., 1999). Moreover, tPA has
been shown to operate in stress-induced neuronal plasticity (Fig. 2) (Pawlak et al., 2003).
The corticosteroid hormones act in memory and learning progress as well as being
involved in stress-caused processing of the neuronal network of the amygdala (Kloet et
al., 1999). Mice deficient in tPA have higher stress tolerance and decreased neuronal
remodeling within the amygdala. In addition, tPA-deficient mice show elevated and
extended strength of corticosteroid levels after restraint stress (Pawlak et al., 2003).
Regulation of hippocampal synaptic reorganization is facilitated by tPA both in a
plasmin-dependent and -independent manner (Pawlak and Strickland, 2002). A
proteoglycan is one target of plasmin-mediated cleavage in the central nervous system
(Wu et al., 2000). tPA can also promote mossy fiber extension without its catalytic
activity (Wu et al., 2000). tPA can also cause neuronal cell death (Tsirka et al., 1996).
Plasmin is involved in hippocampal neuronal cell death and in the destruction of
laminin via activation by tPA (Chen and Strikland, 1997).
The N-methyl-D-aspartate (NMDA) receptors (NMDAR) are classical memory and
learning receptors. The NMDARs are glutamate-gated ion channels. Glutamate is the
principal excitatory neurotransmitter in the mammalian central nervous system
(Melbrum, 2000; Riedel et al., 2003). Activated presynaptic terminals release glutamate,
which binds to NMDR in the plasma membrane of depolarized postsynaptic cells.
Glutamate opens the NMDAR channel allowing Ca2+ (or Na+, K+) to enter the cell.
Elevated Ca2+  acts as an intracellular mediator, activating for example enzymes. Excess
of glutamate causes Ca2+ to enter cells and can result in neurotoxicity. When severe, it
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leads to cell necrosis and in a milder form to cell apoptosis. Glutamate and its receptors
play a critical role in pathological conditions such as cerebral ischemia, traumatic brain
injury, and acute and chronic neurodegeneration. Patients with ischemic stroke are
treated with tPA. While this treatment can cause neuronal cell damage, underlying the
mechanism remains obscure. It has been demonstrated that tPA can augment neuronal
cell destruction by directly cleaving the NMDA receptor (Nicole et al., 2001). tPA-
cleaved truncated NMDAR forms are thought to allow excessive Ca2+ influx, leading to
neurotoxicity and neuronal damage (Traynelis and Lipton, 2001).
Inactive tPA has a beneficial role in brain injury; without its proteolytic activity, it can
activate microglial cells, which then further enhance their activation by releasing tPA
(Rogove et al., 1999).
PAI-1 and PAI-2 in disorders
Disturbances in the amount of PAI-1 in plasma and its structural defects have been
related to pathological conditions such as atherosclerosis (Wiman, 1995) and bleeding
disorders (Diéval et al., 1991). The level of plasma PAI-1 is elevated in patients with
cardiovascular and thromboembolic disease (Wiman, 1995), in those patients with
diabetes (Banfi et al., 2001), and in obesity, which is a factor linked to diabetes (Samad et
al., 1999) (Fig. 2). PAI-1 is also an acute-phase reactant and has been shown to be
induced in mouse hepatic cells in response to tissue injury (Seki et al., 1999). The level of
PAI-1 in tumor extracts is also an independent prognostic marker for recurrence-free
survival of primary breast cancer (Hansen et al., 2003). Regardless of its linkage to many
severe diseases, the origin of plasma PAI-1 remains unknown.
Elevated uPA, uPAR, and PAI-1 levels indicate an increased risk of developing
metastasis in primary breast cancer, whereas elevated levels of PAI-2 suggest a
favorable prognosis (Andreasen et al., 1997; Schmitt et al., 1997). The unusual
intracellular occurrence of PAI-2 has long been a mystery. Cytosolic PAI-2 has been
proposed to participate in host defense against viral infection. PAI-2 is also required for
cell survival, since it inhibits TNF-α-induced apoptosis (Dickinson et al., 1995).
However, in a study where PAI-2 protected cells from certain viral cytopathic effects,
the reason was  discovered to be that PAI-2 mediated interferon production and this led
to expression of antiviral genes (Antalis et al., 1998). PAI-2 also has an unidentified role
in the regulation of carcinogenesis caused by exposure to chemical carcinogens. High
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expression of PAI-2 mRNA is induced rapidly by dioxin in human keratinocytes (Sutter
et al., 1991). The overexpression of PAI-2 in transgenic mice had an enhancing effect on
papilloma formation, some of which progressed to carcinoma, as studied by the
multistage skin carcinogenesis model (Zhou et al., 2001). Moreover, as lesions
progressed to invasive carcinoma, a change occurred in gene expression; PAI-2 was
turned off and uPA turned on. Massive apoptosis in papillomas of control mice
developed after the cessation of PMA application, while in transgenic mice limited
apoptosis occurred. However, in this model, dimethylbenz(a)anthracene (DMBA) and
PMA did not induce endogenous PAI-2 mRNA expression in control mice.
REGULATION OF PLASMINOGEN ACTIVATION
A key question in the plasminogen activation field has been about how the entire
activation cascade is initiated. All enzymes in the PA system are secreted in proforms
(plasminogen, uPA, and tPA). Single-chain (proenzyme) tPA has significantly higher
intrinsic enzymatic activity than uPA (Andreasen et al., 1991; Renatus et al., 1997). In
fact, there has been debate about  whether uPA has any intrinsic enzymatic activity in its
proenzyme form (Collen et al., 1986; Petersen et al., 1988). Some studies suggest that
PAI-1 cannot bind and inhibit pro-urokinase (Andreasen et al., 1986b) and others claim
that it can form reversible enzyme-inhibitor complexes (Manchanda and Schwartz,
1995). PAI-1, is, however, shown to behave as a substrate to its enzyme. After forming a
complex (uPA-PAI-1), uPA is released in active form and PAI-1 in inactive form
(Lawrence et al., 2000). Some reports also describe the proenzyme form of uPA as
having intrinsic enzymatic activity (Lijnen et al., 1991). Activation of pro-urokinase or
plasminogen can occur by kallikrein (List et al., 2000; Selvarajan et al., 2001). In addition,
plasminogen, which circulates in closed conformation, will adopt an open conformation
upon binding on fibrin (Ponting et al., 1992; Wang et al., 2000). Plasminogen itself
undergoes an unusual conformational change when bound to 6-aminohexanoic acid (6-
AHA) which mimics binding to fibrin (Mangel et al., 1990). In this open conformation, it
is believed to be more readily activated.
Endocytosis
Endocytosis regulates the clearance of uPA and tPA from the cell surface, the
circulation, and the extracellular space. Receptor-bound urokinase is most efficiently
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internalized in complex with its inhibitor PAI-1 (Cubellis et al., 1990). This triad is
endocytosed by means of the α 2-macroglobulin receptor/low-density lipoprotein
receptor-related protein (α2M/LRP, same as LRP) from the cell surface (Nyjkær et al.,
1992; Conese et al., 1995; Hussain et al., 1999). Internalized uPAR is recycled to the cell
surface (Nyjkær et al., 1997). The clearance of tPA-PAI (as well as of uPA-PAI-1)
complexes from the circulation occurs via LRP in hepatic cells (Orth et al., 1992). uPAR
is needed to present the uPA-PAI complex to α2M/LRP (Olson et al., 1992). Such a
receptor is not known for tPA.
Effects of hormones, growth factors, and cytokines on plasminogen activation
A retinoic acid receptor response element is located in the human tPA gene (Bulens et
al., 1995). Retinoic acid induces tPA expression in microvascular endothelial, oral
squamous carcinoma, and neuroblastoma cells (Tiberio et al., 1997; Lansink et al., 1998).
More recently, a multihormone responsive enhancer element, which is activated by
glucocorticoids, progesterone, androgens, and mineralocorticoids (Bulens et al., 1997),
was identified in the tPA promoter, and it has four glucocorticoid receptor binding sites.
The human uPA gene enhancer region contains PEA3/AP-1A and AP-1B sites which are
pivotal for the induction of uPA gene transcription by phorbol 12-myristate 13-acetate
(PMA) and epidermal growth factor (EGF) (Rørth et al., 1990; Nerlov et al., 1992). The
PEA3/AP-1 transcription factors have been shown to bind in a cell type-specific manner
on the uPA gene enhancer element (Nerlov et al., 1991). The human tPA gene contains
AP-1 sites (Arts et al., 1997). uPA gene transcription is regulated by the family of nuclear
factor-kappa B (NF-κB) transcription factor proteins (Novak et al., 1991; Newton et al.,
1999; Wang et al., 1999).
Urokinase gene transcription repression is regulated by heterodimeric AP-1
transcription factors (De Cesare et al., 1995). PAI-1 has a glucocorticoid response
element (GRE) site on its gene-regulating elements (van Zonneveld et al., 1988). In
addition, an insulin response element has been mapped to the PAI-1 gene promoter
region (Banfi et al., 2001).
The response of uPAR gene expression to transforming growth factor-β (TGF-β)
varies strongly in different cell lines. This was tested in several human normal and
neoplastic cell lines (Lund et al., 1991). For example, in lung carcinoma cells, TGF-β
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enhanced uPAR mRNA. In addition, the secretion of uPA and PAI-1, but not of tPA,
was affected by TGF-β (Lund et al., 1991).
TGF-β is a well-known stimulator of PAI-1 gene transcription (Laiho et al., 1987;
Sawdey et al., 1989). The TGF-β-inducible transcription factors SMAD3 and SMAD 4
also bind to PAI-1 TGF-β response elements in the PAI-1 gene promoter (Dennler et al.,
1998). TGF-β enhancement of PAI-1 expression can be repressed by glucocorticoids. This
occurs with protein-protein interaction between GR and TGF-β response elements
binding the proteins SMAD3 and SMAD4 (Song et al., 1999). TGF-β regulates the
invasiveness of breast cancer cells by enhancing secretion of uPA, resulting in
stimulation of plasmin formation. The amounts of uPAR, and PAI-1 are also increased.
tPA levels by contrast, are decreased with TGF-β (Farina et al., 1998).
Addition of EGF to human epidermoid carcinoma (A431) cells was demonstrated to
down-regulate epidermal growth receptors (EGFR) with a concomitant increase in
plasminogen activators (Gross et al., 1983). Furthermore, the EGF-induced tPA activity
has been shown to be hidden by PAI-1 in the A431 cell line (George et al., 1990). In a
colon carcinoma cell line, EGF decreased uPA production preceding the uPAR increase.
Insulin and transferrin had no effect on uPA and uPAR expression (Boyd, 1989). In
human squamous cell carcinoma cells, addition of EGF and scatter factor (SF, HGF) had
an inducing effect both on uPA and uPAR (Rosenthal et al., 1998). Nevertheless, MMPs
induced invasion of these cells. Normal human uroepithelial cells produce tPA and uPA
but neoplastic epithelia produce uPA alone. EGF had a slight effect on uPA expression
in neoplastic uroepithelial cells. tPA production, by contrast, diminished after the cells
reached, saturation. Addition of EGF had a considerable increasing effect on tPA
expression in normal epithelium (Dubeau et al., 1988).
Neither Vascular endothelial growth factor (VEGF) nor basic fibroblastic growth
factor (bFGF) alone affected tPA levels, but together they induced tPA in bovine
endothelial cells. Other serum factors seem to be needed because the VEGF- and bFGF-
induced tPA levels were not as high as in the presence of serum (Li and Keller, 2000).
VEGF-B leads to increased expression of uPA as well as of PAI-1 (Olofsson et al., 1998).
In mouse smooth muscle cells, the mitogenic or proliferative response by PDGF or bFGF
was reduced in mice deficient of tPA or uPA. The effect of PDGF was shown to require
the presence of tPA, and bFGF the presence of uPA. Both plasminogen activator mRNAs
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were induced several-fold, uPA with bFGF and tPA with PDGF (Herbert et al., 1997). In
pancreatic carcinoma cells, FGF2 regulates tPA and PAI-1 expression (Escaffit et al.,
2000). In the prostate epithelial cell line, FGF7 induces invasion of cells accompanied by
overexpression of MMP-1 and uPA (Ropiquet et al., 1999).
Table 2. Effect of growth factors, cytokines, and hormones on the plasminogen activation
system.
Effector Cells tPA uPA uPAR PAI-1
RA Neuroblastoma increase no effect no effect no effect
Oral squamous carcinoma cells increase no effect
Microvascular endothelial cells increase increase
EGF Epidermoid carcinoma (A431) increase increase no effect
Colon carcinoma cells decrease increase
Neoplastic uroepithelium cells no effect minor
decrease
Normal uroepithelium cells increase increase
Squamous cell carcinoma (UM-SCC-1) no effect increase increase
HGF/SF Squamous cell carcinoma (UM-SCC-1) no effect increase increase
TGF-β Lung carcinoma (A549) no effect increase increase
Breast cancer cells decrease increase increase
VEGF Endothelia cells (serum needed) increase increase
dFGF Endothelial cells (serum needed) increase increase
bFGF,
FGF-2
Pancreatic  carcinoma increase decrease
FGF7 Prostatic epithelial cells increase
IL-4 Vascular SMC ( serum needed) increase no effect decrease
IFN-γ Vascular SMC decrease no effect
Monocytes increase
Colon carcinoma cells (HTC116) increase
IFN-α Colon carcinoma cells (HTC116) increase
PDGF Vascular SMC increase no effect
IL-1 Keratinocytes increase
Regulation of the plasminogen activation component by cytokines has mostly been
studied in blood cells including monocytes/macrophages and endothelial in cells but
also muscle and epithelial cells. Among the cytokines, interleukin-1β increased tPA
production by the human keratinocytes cell line (Rox et al., 1996). In human aortic
smooth muscle cells, IL-4 increased tPA antigen and IFN-γ decreased the effect of IL-4 in
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the presence of serum. The presence of platelet-derived growth factor (PDGF) was also
shown to have an effect on tPA antigen levels and thereby on muscle cell migration
(Wang et al., 1995). The fibrinolytic potential was stimulated by LPS, TNF-α, and INF-γ
on human endothelial cells (Arnman et al., 1995). Monocytes, which take part in
inflammatory reactions, apparently respond to IFN-γ and TNF-α by increasing uPA
binding on the cell surface; when combined, the two factors are strongly synergistic
(Kirchheimer et al., 1988). IFN-α or -γ upregulates uPAR protein expression in the colon
cancer cell line (Wu et al., 2002). Plasminogen is regulated by IL-6 (Jenkins et al., 1997).
Furthermore, an IL-6 response element has been characterized on a murine plasminogen
promoter sequence (Bannach et al., 2002).
Effect of hydrocortisone on plasminogen activation
The repressing and increasing effects of glucocorticoids are due to the relative impact
of these steroids on different components of the PA system. They repress plasminogen
activation by increasing inhibitor (e.g. PAI-1) synthesis (Bator et al., 1998) or by
decreasing activator synthesis (Cwikel et al., 1984; Busso et al., 1987). In human HT-1080
fibrosarcoma cells, dexamethasone was demonstrated to increase tPA and PAI-1
synthesis and decrease uPA and PAI-2 synthesis, the net result being decreased PA
activity in the cell culture medium (Medcalf et al., 1988). In addition, in HT-1080 cells,
dexamethasone reduces the number of plasmin-binding sites on the cell surface
(Pöllänen, 1989).
Glucocorticoids can also have the opposite effect on the synthesis of the two PA
activators (Busso et al., 1986) without affecting inhibitors in the same cells. In human
embryonic or tumor-derived carcinoma cell cultures, dexamethasone decreased
plasminogen activator activity but had no repressive effect on six melanoma-derived
cell cultures, which mainly produced tPA (Roblin and Young, 1980). In fact,
dexamethasone increased tPA activity in these cultures. In rat hepatic cells,
dexamethasone increased tPA gene transcription, and when combined with cAMP, tPA
was upregulated further (Kathju et al., 1994). The increase in tPA activity by
dexamethasone was also seen in rat granulosa cells under the influence of certain
hormones and growth factors (Jia et al., 1990). However, in human ovarian carcinoma
cells, dexamethasone decreased total plasminogen activator activity by 95% (Amin et al.,
1987). The decrease in uPA activity preceded the effect on tPA activity. Moreover, there
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was a marked effect on cell morphology by dexamethasone. In human embryonic lung
cells, glucocorticoids have a suppressive effect on plasminogen activator synthesis
(Rifkin, 1978).
One example of the impact of hydrocortisone on plasminogen activator(s) is given by
tissue remodeling events such as mammary gland involution. Hydrocortisone inhibits
mammary gland involution (Ossowski et al., 1979; Feng et al., 1995). uPA, as well as
metalloproteinases, is strongly upregulated in mammary gland involution. In
hydrocortisone-treated mice, the involution regresses, and the proteases (including
uPA) are strongly repressed (Lund et al., 1996). Another example of tissue remodeling is
provided by castrated rats. Prostate involution was accompanied by uPA and tPA
upregulation, which was retarded by the administration of hydrocortisone, followed by
downregulation of the uPA and tPA activities (especially the 30-kDa form of uPA)
(Freeman et al., 1990). Benign and malignant prostate tissues were shown to contain
both types of plasminogen activators; albeit more tPA than uPA. The presence of
hydrocortisone in prostate tissue organ culture led to a marked decrease of plasminogen
activators (Camiolo et al., 1984).
Early reports demonstrate that the administration of corticotrophin significantly
decreases the elevated fibrinolysis seen in patients with liver cirrhosis (Kwaan et al.,
1956). In rat tongue organ culture, the squamous tongue epithelium was shown to
produce tPA. The addition of hydrocortisone to the culture medium led to a marked
repression of tPA activity (Wünschmann-Henderson and Astrup, 1974). In the same
study, hydrocortisone-treated cultures were observed to have better tissue integrity,
although this could not been confirmed to be the result of the decrease in tPA.
Maintenance of mammary epithelial cell differentiation is partly due to extracellular
matrix turnover caused by the inhibitory effect of glucocorticoids (Casey et al., 2000).
Human keratinocytes secrete both plasminogen activators and PAI-1 in vitro (Jensen
et al., 1990), and their secretion depends on the differentiation state of the epithelial cell.
Furthermore, immunohistological staining of uPA and tPA in organotypic explants
showed that tPA and uPA were localized in different cell layers of stratified
keratinocytes (Chen et al., 1993). Hydrocortisone has also been studied in murine
keratinocytes, where it was found to have an increasing effect on PAI-1 mRNA and
antigen levels, but not on tPA and uPA mRNA (Bator et al., 1998). In this system,
plasminogen activation was mainly suppressed due to the increased PAI-1 production.
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Table 3. Effect of hydrocortisone or dexamethasone on plasminogen activation.
Cells PA-activity tPA uPA PAI-1 PAI-2
Fibrosarcoma-HT1080 decrease increase decrease increase decrease
Melanoma cell lines:
Malme-3M no effect no effect
RPMI 8252 no effect no effect
SK-MEL-2 no effect no effect
SK-MEL-26 no effect no effect
SK-MEL-27 no effect no effect
MeWo no effect no effect
Embryonic lung cells inhibit
Embryonal kidney cells (HEK) inhibit decrease
Uveal melanocytes inhibit decrease
Renal carcinoma (Caki-1) inhibit decrease
Renal carcinoma (Caki-2) inhibit
Lung adenocarcinoma (Calu-3) inhibit
Mammary carcinoma (MDA-MB-231) decrease decrease increase
Rat hepatoma cells decrease no effect increase
Ovarian carcinoma (OVCA 433) decrease decrease decrease
Rat ovarian granulosa cell increase
Murine keratinocytes decrease no effect no effect increase
Mammary gland involution inhibit decrease decrease
Rat prostate gland involution inhibit decrease decrease no effect
Neoplastic prostate organ culture decrease decrease
Benign prostate organ culture decrease decrease
Rat organ tongue culture inhibit decrease
Patients with cirrhosis, plasma levels decrease
INTERACTION OF PLASMINOGEN ACTIVATION COMPONENTS WITH
ADHESION MOLECULES
In vitro, urokinase is localized on the cell surface at focal contacts, tips of microspikes,
cell-cell contacts, and lamellipodia (Pöllänen et al., 1987, 1988). uPAR is GPI-anchored
(Ploug et al., 1991), which prompted researchers to look for associated molecules.
Finding an explanation for those uPA-uPAR-related cellular events that were
independent of uPA’s proteolytic activity (e.g. cell migration caused by the formation of
uPA-uPAR complexes) was of particular interest (Gudewicz and Gilboa, 1987; Fibbi et
al., 1988; Del Rosso et al., 1990).
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Earlier findings of PAI-1 being deposited on the substratum of cell cultures (Pöllänen
et al., 1987) and forming complexes with vitronectin while retaining its activity (Salonen
et al., 1989) suggested that PAI-1 is more than an inhibitor. The first hints that PAI-1
participated in cell adhesion came from Ciambrone and McKeown-Longo (1990), who
found that the addition of PAI-1 antibodies disturbs cell adhesion. This was shown to be
due to the disruption of vitronectin-dependent adhesion. They later, demonstrated that
the localization of uPA depends on the cell substratum. In cells on growing vitronectin-
coated surfaces, uPA was localized in focal contact-like areas but not on fibronectin, on
which uPA was evenly spread on the cell surface (Ciambrone and McKeown-Longo,
1992). Another group also identified uPA and uPAR as being involved in cell adhesion.
The adhesion of human myeloid cells provoked by PMA could be abolished by uPA
antibodies and reversed by the addition of the ATF-fragment of uPA (Nusrat and
Chapman, 1991). Furthermore, PAI-1 was suggested to be responsible for the reduced
adherence, but the reason was presumed to be increased PAI-1-uPA turnover (Waltz et
al., 1993). While, Waltz and Chapman (1994) subsequently verified vitronectin-uPA
dependent adhesion, they did not succeed in characterizing the vitronectin-binding sites
(other than integrins) on the cell surface. However, in the same year vitronectin was
reported to bind with high affinity to uPAR on cell the surface (Wei et al., 1994b), being
further strengthened by concurrent uPA binding to its receptor. Vitronectin-uPAR
binding and its reversibility by PAI-1 was demonstrated in human endothelial cells, but
this was shown to occur only with soluble vitronectin and there was no involvement of
uPAR-vitronectin in substratum-attached vitronectin (Kanse et al., 1996).
Before long it came evident that uPAR is in close contact with integrins,  as it could be
specifically co-capped with CR3 (CD 11b/18, β2-integrins) on neutrophil membranes
(Wei et al., 1994a) and was co-immunoprecipitated with β2-integrin antibodies from
monocyte lysates (Bohuslav et al., 1995). A few years later, the interaction between
uPAR and integrins was confirmed in another study (this particular work focused on β1-
integrins). In addition, it was proved that uPAR modifies integrin function and is found
in caveolin-integrin complexes on the cell membranes (Wei et al., 1996). In the same
year, uPAR and PAI-1 were reported to have the same binding sites on vitronectin (not
identical but overlapping), and thus, PAI-1, which has a higher affinity to vitronectin
could compete for uPAR binding on vitronectin (Deng et al., 1996). tPA was also capable
of reversing the inhibitory effect of PAI-1 on adhesion. The relative amounts of uPA and
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PAI-1 determine whether an adhesive or nonadhesive effects occurs; more PAI-1 favors
cell detachment from the substratum, while more uPA supports cell adhesion (Loskutoff
et al., 1999).
This picture became even more complicated when another group showed that PAI-1
is capable of inhibiting the migration of smooth muscle cells. This is possible due to
sterical hindrance (Stefansson and Lawrence, 1996), since the PAI-1 attachment site on
vitronectin overlaps with the binding site of vitronectin on the αvβ3-integrin. This was
confirmed by others (Kjøller et al., 1997). Yebra et al. (1996) demonstrated that αvβ5 was
needed for cell migration via uPA-uPAR on vitronectin and not the αvβ3-integrin. It has
further been demonstrated that in HT-1080 cells, uPAR co-localizes with several
integrins, including β1 and β3, and it assembles with αv, α 3, α 5, or α6; the assembly
depends on the composition of the extracellular matrix (Xue et al., 1997). In cell culture,
PAI-1 is also found under the cells bound to the substratum. On the substratum, PAI-1
is bound to vitronectin, which in turn originates from the serum, if not produced by the
cells. Immobilized PAI-1 can mediate adhesion and spreading of human myogenic cells,
and this could be abolished with antibodies against the integrin αvβ3 (Planus et al., 1997).
Table 4. Plasminogen activation components and adhesion molecules.
PA
Components
Interacting
molecules
Adhesive/deadhesive
functions
uPAR VN adhesion
uPAR+PAI-1 VN detachment
uPAR+uPA VN
αvβ3, α5β3
adhesion
uPAR+uPA
+PAI-1
VN
αvβ3, αvβ3
detachment
uPAR+uPA
+PAI-1
VN
αvβ3, αvβ5
LRP
detachment
integrin inactivation
endocytosis
uPAR
(uPA?)
α4βl, αvβ3
α9β1
cell-cell adhesion
Waltz et al. (1993) proposed that uPA-PAI-1 might cause cell detachment by PAI-1-
uPA turnover, but this theory received little attention at that time (Waltz et al., 1993). In
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more recent investigations LRP and uPA-uPAR-PAI-1-integrin turnover has been
demonstrated involved in cell adhesive/deadhesive functions (Czekay et al., 2001, 2003)
(Table 4). The action seems to depend on the amount of uPAR versus integrins. Czekay
et al. (2003) demonstrated that PAI-1 detached cells by disrupting the uPAR-vitronectin
or the integrin-vitronectin interaction. In both situations, the PAI-1-mediated cell
detachment was an uPA-dependent mechanism. They suggested that detachment of
cells by PAI-1 depend on the engaged amount of uPA-uPAR-integrin complexes relative
to the total amount of active integrins. Furthermore, they revealed that in the PAI-1-
mediated detachment of cells, integrins were inactivated first and then the entire
adhesion complex (PAI-1-uPA-uPAR-integrin) was internalized via LRP (Czekay et al.,
2003). Internalization of the complex occurs via direct interaction between uPAR and
LRP (Czekay et al., 2001).
uPAR has been thought to associate with integrins and perhaps modify their
functions (Simon et al., 2000), but recently, uPAR has been reported to in fact be a ligand
for integrins. uPAR was shown to directly compete with other ligands in binding to
integrins (Tarui et al., 2001). In addition, uPAR appears to be a ligand, heterotypic i.e. it
binds to neighboring cell integrins.
34
AIMS OF THE STUDY
This study aimed to gain insight into the mechanisms regulating plasminogen
activation.
Specific aims were:
-to study localization, mobility, and associated molecules of the uPAR on the cell
surface (I).
-to study regulation of uPAR expression in retinal pigment epithelial cells (II).
-to study the effect of hydrocortisone and other regulatory molecules on the
expression of PA genes in normal and immortalized epithelial cells (III).
-to study in vivo expression of tPA in normal, premalignant, and malignant cervical
epithelium (IV).
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MATERIALS AND METHODS
Cell cultures
Human RD rhabdomyosarcoma cells were from the American Type Culture Collection and
human embryonic skin fibroblasts (HES) were established by standard procedures. Both cell
lines were cultured in Eagle’s minimal essential medium (MEM) supplemented with 8% fetal
calf serum (FCS), glutamine, penicillin, and streptomycin. Human retinal pigment epithelial
(RPE) cells were obtained from Dr. Michael Boulton, Royal Eye Hospital, Manchester, United
Kingdom. The RPE cells were cultured in the presence of 20% FCS, glutamine, penicillin, and
streptomycin in Coon’s Ham’s F12 medium. Human cervical epithelial cells (HCE) transfected
with human papillomavirus (HPV-16) DNA (Zheng et al., 1994) were grown in Dulbecco’s
Modified Eagle Medium (DMEM) and Nutrient MIX-F12 (1:1) supplemented with 2% fetal
bovine serum (FBS), streptomycin, penicillin, glutamine, cholera toxin, EGF, hydrocortisone,
insulin, and transferrin together with triiodothyronine (T3).
Normal human bronchial epithelial (NHBE) cells (Clonetics) and adeno-12/SV-40 virus-
transformed human bronchial epithelial cells (BEAS-2B) (Reddel et al., 1988) from Dr. Curtis
Harris, National Cancer Institute, Bethesda, MD, were grown in bronchial epithelial cell basal
medium (BEBM) (Clonetics) supplemented with bovine pituitary extract, hEGF, epinephrine,
hydrocortisone, insulin, retinoic acid, T3, transferrin, and antibiotics.
Immunofluorescence (RD and HES cells)
A live staining method was used for uPAR monoclonal antibodies; i.e. primary uPAR
antibodies (Rønne et al., 1991) were applied at ~0°C on cells before any fixation. After fixation
with methanol, the cells were stained with rabbit anti-mouse antibodies conjugated with
fluorescein isothiocyanate (FITC). For matrix and integrin antibodies, the cells were first fixed
with cold methanol, then exposed to primary antibodies, and finally secondary rabbit anti-
mouse or donkey anti-rabbit FITC-conjugated antibodies were added.
Double immunofluorescence was carried out at 0°C with uPAR antibodies and then the cells
were fixed with cold methanol. After fixation, staining was carried out in the following order:
tetramethyl rhodamine isothiocyanate (TRITC) conjugated donkey anti-mouse, rabbit antibodies
to vitronectin receptor or vinculin, and FITC-conjugated donkey anti-rabbit IgG. Washing was
done at the beginning and end of each incubations and after fixation. Antibodies were diluted in
Dulbecco’s buffer supplemented with 0.5% BSA.
Antibody-induced clustering (RD and HES cells)
RD and HES cells were grown as mentioned above, except that the cells were treated with
uPA or left untreated. Before clustering, uPAR or uPA antibodies were applied at ~0°C. After
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primary antibodies, clustering of uPAR/uPA was done with rabbit anti–mouse IgG at 37°C for
15 min. Cell layers were fixed with cold methanol and treated with FITC-conjugated swine anti-
rabbit or rabbit anti-mouse IgG.
Immunoferritin electron microscopy (RD cells)
Ultrastructural localization was evaluated by immunoelectron microscopy based on the
ferritin-labeling technique. Staining was carried out at 0°C in the following order: primary
antibodies (uPAR), rabbit anti-mouse IgG, mouse anti-horse ferritin, and ferritin. After each
incubation, the cell layers were washed. Cells were fixed with a mixture of paraformaldehyde
and glutaraldehyde in phosphate buffer, after which sodium borohybride was applied. Post-
fixation was done with OsO4 in phosphate buffer. Cells were then dehydrated with graded series
of ethanol, with or without uranyl acetate, at the 94% ethanol stage. Samples were mounted in
Epon, after polymerization were sectioned, and sections were stained with lead citrate and
uranyl acetate. Samples were observed with a JEOLJEM-1200EX electron microscope.
Flow cytometric analysis (RPE cells)
uPAR protein quantity was determined on the surface of RPE cells. Cells were detached from
dishes and washed with 1% serum in PBS. uPAR monoclonal antibodies were applied to cells on
ice. After washings, FITC-conjugated anti-mouse IgG was added. FITC-labeled cells were
analyzed with FACScan (Becton Dickinson).
EIA for uPAR antigen (RPE cells)
The amount of uPAR was measured from RPE cell lysates. RPE cells were lysed in cold TRIS-
buffer containing 1% Triton X-114 and protease inhibitors. Samples were incubated in wells
coated with polyclonal uPAR antibodies. After antigen binding, the wells were rinsed and
detection was accomplished with the with biotinylated anti-uPAR monoclonal antibodies and
avidin-peroxidase method.
RNA extraction and Northern blotting (HCE16/3  and RPE cells)
Guanidium isothiocyanate lysis and phenol chloroform extraction or the CsCl gradient
centrifugation method were used to isolate total cellular RNA. RNA was quantified
photometrically and samples were fractionated on agarose gel and then transferred to Hybond-
N nylon membranes. For nonradioactive detection, hybridization was carried out in the solution
containing formamide, sodium citrate (SSC), N-laurosyl sarkosine, sodium dodecyl sulfate
(SDS), blocking solution (Boehringer Mannheim), and digoxigenin-labeled probe. For
radioactive detection, hybridization was carried out in a solution of formamide, Denhardt’s
solution, sodium chloride-sodium phosphate EDTA buffer (SSPE), and SDS. After hybridization,
filters were washed. Digoxigenin-labeled blots were submitted to immunological detection
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using anti-digoxigenin antibody conjugated with alkaline phosphatase, followed by
chemiluminescent (CSPD) detection. For radioactively labeled blots, [α-P32]-dCTP and a
random-primed DNA labeling kit were used.
Immunocapture assay for plasminogen activators (HCE16/3 and RPE cells)
Multiwell plates were coated with uPA or tPA polyclonal antibodies. Growth medium
supernatants and standard dilutions of uPA or tPA enzymes were added to the wells. After
incubation, the wells were washed and plasminogen was added to the specific buffer for uPA or
tPA. Plasmin substrate (ZLS-Lys-SBzl) was also added to the buffer. uPA and tPA activities
were read with a photometer reader at 10-min intervals.
PAI-1 EIA (HCE16/3 cells)
Enzyme immunoassay for PAI-1 was performed in the following order. Multiwells were first
coated with mouse anti-human PAI-1. After incubation, the wells were washed and blocked.
Samples were then added, and after their incubation, detection was accomplished with
biotinylated PAI-1 monoclonal antibody, and peroxidase-conjugated streptavidin and substrate.
The reaction was stopped and absorbances of color were read by a multiscanner photometer.
Zymography (HCE16/3 cells)
Samples were run in SDS-PAGE gels under nonreducing conditions, after which the gels
were washed thoroughly with Triton X-100 in PBS. Casein gels were made with agarose which
contained milk powder and plasminogen in a Tris-HCl buffer, pH 7.4. Washed SDS gels were
placed on the top of the agarose gels and incubated at 37°C or at 4°C. Anticatalytic antibodies
were added between gels to inhibit plasminogen activators.
Immunoprecipitation of PAI-1 (HCE16/3 cells)
Immunoprecipitation of PAI-1 from the growth medium was achieved with a monoclonal
antibody to PAI-1. The immunoprecipitate complex was captured by Protein-A Sepharose,
which was pretreated with rabbit anti-mouse IgG. The immunoprecipitate complex was washed
and eluted a using nonreducing SDS sample buffer. Immunoprecipitates were separated by
SDS-PAGE  after which the SDS gels were ready for zymographic analysis.
Tissue specimens
The following 104 archival, formalin-fixed, paraffin-embedded blocks were studied: normal
cervical epithelium (n=7), condylomatous atypia (n=13), condyloma acuminatum (n=1), mild
dysplasia (cervical intraepithelial neoplasm [CIN I]; n=10), moderate dysplasia (CIN II; n=11)
and severe dysplasia or carcinoma in situ (CIN III; n=20) of the dysplastic squamous epithelium,
as well as microinvasive epidermoid carcinoma (n=9), invasive epidermoid carcinoma (n=13),
adenocarcinoma (n=11), and adenosquamous carcinoma (n=9) of the uterine cervix. All tumor
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samples were from primary lesions. Paraffin blocks of tissue specimens were supplied by the
Department of Pathology, Helsinki University Central Hospital.
Antibodies and probes
Monoclonal antibodies to human tPA (PAM-3) and uPA (3689) were provided by American
Diagnostica (Greenwich, CT) and to human Ki-67, neurofilament protein, and vimentin (clone
V9) by DAKO A/S (Glostrup, Denmark). For the RNA in situ hybridization experiments,
riboprobes were used. for cDNA fragments; a 2.3-kb PstI fragment of human tPA was from the
American Type Culture Collection, Rockville, MD. The templates for riboprobes with either an
SP6 or T7 promoter sequence at the 5' end were produced by polymerase chain reaction. The
probe size was 243 bases for tPA (position 1431-1674) and was labeled with digoxigenin-uridine
triphosphate by in vitro transcription. In negative control hybridization, probes in sense
orientation were used.
Immunohistochemical detection of tPA
Immunohistochemistry of tPA was done by using a Ventana Gen II automated
immunohistochemical stainer (Ventana Medical System, Tucson, AZ). Three micromillimeter
thick sections on SuperFrost Plus slides (Menzel-Gläser, Braunschweig, Germany) were assayed
for tPA and neurofilament antigens using the Ventana Basic Alkaline Phosphatase Red detection
kit. For Ki-67 and vimentin antigens Ventana Basic DAB detection kit was used. The kits
included a universal biotinylated secondary antibody. The sections were deparaffinized and
hydrated. Tissue slides were pretreated in a microwave oven, cooled with distilled water, and
placed in a Ventana Tris-based APK buffer (Ventana Medical Systems). The instrument was
programmed for a 28-min incubation with primary antibody, a 4-min postfixation, and
incubation with biotinylated secondary antibodies. The complex was visualized by avidin
alkaline phosphatase conjugate (RED), avidin horseradish peroxidase (DAB) and followed by
alkaline phosphatase substrate Fast Red, peroxidase substrate diaminobenzidine (DAB).
Enhancement was done with magnesium chloride in the Red and copper sulfate in the DAB
detection kit. The program included counter-staining with hematoxylin and post-counter-
staining with Ventana Bluing Reagent. Sections were dehydrated with ethanol and xylene and
mounted with Entellan®-treated coverslips.
Semiquantitative scoring of tPA level was done visually: tissues were scored using 3 for dark
red staining (strong), 2 for medium red staining (moderate), 1 for weak but positive staining
(mild), and 0 for negative or very faint staining.
In situ hybridization
ISH was performed using the Ventana Gen II Slide Stainer. The program used was the
"Ventana Regular" protocol. Sections were first deparaffinized and rehydrated in graded series
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of ethanol. After rinsing in distilled water treated with 0.1% diethylpyrocarbonate (DEP), the
slides were kept in APK buffer until the in situ hybridization procedure. The sections were
treated for 8 min with protease before hybridization at 45°C for 14 h. The hybridization mixture
contained 50% formamide and 4 x SSC. Three washes after hybridization were performed at
65°C for 8 min in 1 x SSC, 0.5 x SSC, and 0.1 x SSC, respectively. Monoclonal anti-digoxigenin
clone DI-22 (Sigma, St Louis, MO) was incubated with the sections for 28 min. The probe was
detected with the Ventana 3,3'-diaminobenzidine tetrahydrochloride (DAB) biotin avidin
detection kit. The sections were dehydrated and mounted with coverslips treated with
Entellan® and then analyzed with an Olympus light microscope.
Immunohistochemistry and in situ hybridization results were photographed with a Zeiss
Axiophot 2 image automated microscope.
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RESULTS AND DISCUSSION
Localization and lateral mobility of uPAR and effect of TGF-β on uPAR expression
(I, II)
The distribution of uPA reflects the uPAR distribution on cell membranes (Pöllänen
et al., 1988). We confirmed that uPAR is also found at the focal contacts, tips of
macrospikes, lamellipodia, and cell-cell contacts of human rhabdomyosarcoma and
embryonic fibroblasts (I). However, in some cell lines, mostly epithelial, uPAR has not
been found in focal contacts. In Met24 melanoma cells, for instance, it was distributed in
a punctate pattern and localized in caveolae (Stahl and Mueller, 1995). In human amnion
WISH cells, uPAR was also localized in a punctate pattern all over the cell membranes
(Busso et al., 1994).
We have also observed that uPAR in a punctate pattern on plasma membranes of
human amnion epithelial cells. This was especially the case with confluent cells, because
in sparse and scattered cell cultures, uPA was found in focal adhesion plaques on
plasma membranes (unpublished results). uPAR can be differentially distributed
depending on cell type, but distribution may also depend on the condition of cells: i.e.
whether they are in an adhesive state or in a migratory or stationary state. Moreover, in
study I, uPAR in migratory RD cells gave a spot-like staining on the cell surface and not
an elongated striae-like pattern.
Colocalization with uPAR was found with αvβ3-integrins (I). It has subsequently been
reported that uPAR colocalizes with numerous integrins, e.g. with αvβ5- αvβ3- and α3β1-
integrins, depending on the cell type studied (Yebra et al., 1996; Planus et al., 1997;
Carriero et al., 1999; Ghosh et al., 2000).
Ciambrone and McKeown-Longo demonstrated in 1992 that vitronectin is responsible
for clustering of uPA to the focal adhesion contacts on fibrosarcoma cells, although they
later reported that vitronectin and its αvβ5-receptor were necessary but not sufficient to
cluster uPA to focal contacts (Wilcox-Adelman et al., 2000). Integrins affect plasminogen
activation in many ways. They not only target uPAR/uPA on the plane of the plasma
membrane but also influence the expression of uPA/uPAR (Ghosh et al., 2000; Hapke et
al., 2001; Silvesteri et al., 2002). We found uPA to be one (perhaps not the only)
candidate participating in the driving or anchoring of uPAR to focal contacts on the cell
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membrane (I). This was based on the unoccupied receptor being diffusely distributed,
while the occupied receptor was mainly bound to restricted areas on fibroblast cell
membranes (I). In addition, in RD rhabdomyosarcoma cells, which secrete high amounts
of uPA, uPAR was mainly located in these restricted areas (focal adhesions) (I).
Furthermore, antibody-induced clustering suggested that uPAR, which was localized at
the focal contacts, was not laterally mobile (Fig. 3). Clusters were seen within the focal
contacts in both fibroblasts and RD cells.
We detected uPAR under cell-cell adhesion sites (I). This was seen as a continuous
line between adjacent adhering cells at the light microscopic level. In the
electronmicroscopic study, uPAR was seen organized focally between adjacent cells (I).
Subsequent studies by others have shown an interaction of uPAR with integrins on the
adjacent cells (Tarui et al., 2001).
In amnion WISH cells, the addition of exogenous uPA in serum-free conditions had
no effect on the distribution of uPAR (Busso et al., 1994), although cell morphology was
affected. Moreover, uPA was reported to not necessarily be required for uPAR
localization to focal contacts on the human glioma cell surface (Hedberg et al., 2000).
This was based on the finding that uPAR was detected in focal contacts when the cells
were cultured in the presence of serum or certain serum fractions and on glioma cells
being known not to produce uPA. Glioma cells were concluded not to need “classical
focal adhesions” for their migration, nor was uPAR needed in the focal adhesions of
these cells to migrate. Moreover, the authors suggested that uPAR could preferentially
be an adhesion receptor in glioma cells because the presence of uPAR at the focal
adhesions correlated with cell spreading rather than with elongated cell morphology.
They also demonstrated that high molecular weight components of serum could cause
the localization of uPAR to focal contacts.
Although uPAR/uPA-PAI-vitronectin and its receptor take part in cell adhesion and
cell migration, they (uPAR, uPA, PAI-1) are an additional mechanism; they are not
obligatory for cells to be able to adhere or migrate.
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Figure 3. A model of in vitro and in vivo induced distribution of uPAR on the
cell surface. Occupied uPAR is clustered at  focal contacts (C), and
unoccupied receptors have a uPAR punctated pattern all over the
cell membrane (D).  
C. Occupied uPAR
   - restritced
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TGF-β induced rapid and transient uPAR mRNA expression in retinal pigment
epithelial (RPE) cells (II). This was seen in the uPAR protein expression level at 48 h on
cell membranes. The appearance of uPAR protein in the cell lysate and on the cell
membranes reflects a transient effect of TGF-β on uPAR production by these cells. The
highest amount of uPAR in cell lysates was measured at 24 h, with a decrease occurring
thereafter. Induction of uPAR release by TGF-β could also be seen in the growth
medium. Interferon-γ (IFN-γ) had an increasing effect on uPAR gene transcription, but
this was not translated to the protein level (II). In fact, a decrease occurred in uPAR
protein levels of RPE cells with the addition of interferon. Some reports claim that in
human monocytes IFN-γ increased uPAR, but addition of uPA together with IFN-γ
decreased the number of uPA-binding sites on the cell surface (Kirchheimer et al., 1988).
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uPA can increase its own or uPAR expression in bronchial epithelial cells (Idell, 2002).
IFN-γ, as well as IFN-α, has been shown to regulate plasminogen activation by
decreasing PAI-1 expression, resulting in increased uPA activity (Sirén et al., 1994).
uPAR mRNA turnover may also be regulated by IFN-γ. Cytokines and growth factors
expressed in such eye diseases as PVR and ARMD influence the development and
severity of these diseases. IL-1 enhances uPAR expression as well as collagenolytic
activity with increased RPE cells invasion throughout extracellular matrix. RPE cell
invasion could be abolished by PAI-1 but not by collagenase inhibitor (1,10-
phenantroline). Nevertheless, PAI-1 and collagenase inhibitor were shown to be able to
inhibit proteolysis of extracellular matrix (Elner, 2002). A recent study concluded that
uPA, tPA, and plasminogen, but not uPAR, were involved in CNV which is severe form
of ARMD. All PA mRNA components were expressed in human CNV patient
specimens (Rakic et al., 2003). The same study showed that tPA-, uPA-, and
plasminogen-deficient mice were resistant to choroidal neovascularization. Previous
reports have also indicated that new vessel formation is inhibited in PAI-1-deficient
mice (Lambert et al., 2001). Our results demonstrate that TGF-β can disrupt the balance
of plasminogen activation by increasing uPAR expression. Increased uPAR may have an
enhancing effect on proteolytic activity, but it also influences the migratory behavior of
RPE cells.
Hydrocortisone has a strong impact on plasminogen activators (III)
Hydrocortisone was found to be a potent repressor of plasminogen activators in the
HCE16/3 cervical epithelial cell culture system. Plasminogen activators and their
inhibitor PAI-1 were studied at the protein and RNA expression levels. We also
evaluated the effect of hydrocortisone on plasminogen activators in two additional cell
lines, namely BEAS-2B (adeno/Sv-40 hybrid transfected and immortalized bronchial
epithelial cells) and its normal counterpart NHBE (normal human bronchial epithelial)
cells. The main finding was that tPA was under the strong repressive control of
hydrocortisone. Its gene expression started to increase 48 h after the withdrawal of
hydrocortisone. By contrast, uPA gene induction was seen as early as 3 h after
withdrawal of hydrocortisone. None of the other growth supplements in the
conventional epithelial cell culture medium, including 2% serum (FBS), EGF, insulin,
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cholera toxin, and transferrin together with T3, had such an effect on tPA production in
HCE16/3 cells. EGF increased the expression of uPA in these cells.
Earlier studies have revealed that both activators respond to glucocorticoids and that
the extent of the effect seems to depend on cell type. Recent publication states that the
tPA gene has four glucocorticoid receptor (GR) binding sites that act as enhancers as
well as cooperating with a retinoic acid (RA) response element (Bulens et al., 1997). GR
binding sites have thus far not been found in the uPA gene structure. However, uPA
does have has AP-1 binding sites, and GR repressive function has been shown to go
through AP-1 transcription factors (De Cesare et al., 1995).
Both PAI-1 and tPA plasma levels display circadian rhythm, the reason for which
remains unknown. The tPA activity is lowest early in the morning and increases during
the day, while PAI-1 activity is highest in the morning (Wiman, 1995). They both are
regulated by glucocorticoids and contain glucocorticoid receptor response elements
(GRE) in their genes. Thus, it is worth noting that cortisol also displays a circadian
rhythm. In human plasma, cortisol is in its maximum level early in the morning,
declining throughout the day (Brook and Marshall, 1999).
Expression of tPA in the stratified squamous epithelium of human uterine cervical
tissues (IV)
Based on our previous study (III), we were interested in investigating tPA antigen
and mRNA expression. We showed that tPA is produced in normal, dysplastic stratified
epithelium as well as malignant tissues of the human uterine cervix. Intense tPA antigen
staining was localized in the 3-4 cell layers above the basal cells of the stratified
squamous epithelium (IV). This was seen both normal, dysplastic (CIN I-III) and
microinvasive epidermoid carcinoma specimens. Normal, condyloma and CIN I uterine
cervical epithelium mostly gave strong staining intensity, however, in CIN II and CIN
III dysplastic tissue specimens there was a tendency for decreased staining intensity
along with tumor progression. The vessel wall of the endothelial cells and granulocytic
blood cells within the vessels were tPA antigen-positive (IV).
An earlier study has shown tPA mRNA to be localized mainly in the middle layers of
dysplastic stratified squamous epithelium of the human uterine cervix (Riethdorf et al.,
1999). Our results indicated the presence of tPA mRNA in the basal and parabasal layers
of the stratified epithelium (IV). In addition, another group has reported that tPA
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antigen was expressed from the basal to the upper layers of the stratified epithelium in
precancerous lesions (Larsson et al., 1987). We could not confirm this. tPA
immunoreactivity mostly was evident starting from a 3-4 layers above the basal cell
layer in the stratified epithelium (IV).
In Epidermoid carcinoma tissue specimens, tPA immunoreactivity was mostly at a
strong to moderate level of intensity. By contrast, in adenocarcinoma specimens,
staining gave mostly weak and negative color intensity. Two of the adenocarcinoma
patient specimens exceptionally showed a very strong staining of tPA antigen. For these
specimens, in situ hybridization was performed. Interestingly, this showed a strong but
heterogeneous localization of tPA mRNA. tPA mRNA was clearly expressed in a certain
population of cancer cells. Heterogeneous distribution was also detected at the antigen
level in the same specimens. tPA mRNA was found in adenocarcinoma cancer cells but
not in epidermoid carcinoma samples. However, around the epidermoid carcinoma, the
stromal cells were tPA mRNA-positive. tPA antigen was also detected in stromal cells.
The cells, which displayed the positive signal, were inflammatory and fibroblast-like.
Around the cancer cell islands, positive tPA immunostaining was frequently seen. Low
tPA antigen or activity levels have been shown to predict poor prognosis in breast
cancers. In the case of colorectal cancer, uPA, uPAR and PAI-1/2 levels are elevated, but
tPA decreases with progressing carcinogenesis. A decrease in tPA is seen especially
when compared with the corresponding normal mucosa. High tPA antigen and activity
levels in normal mucosa correspond to good prognosis of patients (Ganesh et al., 1994;
Verspaget et al., 1995). High tPA expression detected by immunohistochemistry in the
cancer cells of primary melanoma predicts a long metastasis-free interval (Ferrier et al.,
2000).
tPA is apparently necessary for cancer invasion, growth and angiogenesis. In
humans, this has been demonstrated pancreatic carcinomas, oral squamous cell
carcinoma, and in neuroblastoma cell lines (Tiberio et al., 1997; Uchida et al., 2001; Díaz
et al., 2002). In human pancreatic cancer cell lines, tPA was overproduced in well-
differentiated cancer cells together with uPAR (Paciucci et al., 1998). In oral squamous
and neuroblastoma cells, RA enhances tPA activity and invasion of cancer cells, which is
accompanied by proMMP-2 and -9 activation in oral cell carcinomas (Tiberio et al., 1997;
Uchida et al., 2001).
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We found tPA mRNA and antigen to be located in different layers in the stratified
squamous epithelium. The method used for in situ hybridization did not give any
background, accurate visualization of tPA mRNA was achieved. tPA may have
additional roles to that of being a fibrinolytic enzyme in normal epithelial cells.
Plasminogen activators have been linked to or suggested to play a role in cell
differentiation by many investigators (Wilson and Francis, 1987; Neuman et al., 1989;
Jensen et al., 1990; Chen et al., 1993). Secretion of tPA is a differentiation marker in
embryonal carcinoma cells which can be induced to differentiate by retinoic acid
(Strickland et al., 1980; Watkins et al., 1992). Normal urothelium secretes uPA and tPA,
but tumor cell lines of urothelium secrete only uPA (Dubeau et al., 1988). Results from
an immunohistological study have suggested that tPA might be a marker of “end-stage
differentation” in vivo (Dubeau et al., 1988). However, the targets for plasminogen
activators/plasmin in differentiating normal cells remain unclear. Some studies have
indicated that adhesive molecules, such as fibronectin and fibrinogen/fibrin, hinder the
cell differentiation process, and this could be overcome by activation of plasminogen
(Selvarajan et al., 2001; Suelves et al., 2002). In adipocyte differentiation, kallikrein was
shown to activate plasminogen but not tPA or uPA (Selvarajan et al., 2001).
Our study revealed that tPA is produced, possibly in large amounts in human normal
and dysplastic stratified cervical epithelium. While tPA expression may be turned off in
cancer cells with cervical tumor progression, we detected tPA antigen in most of the
epidermoid carcinoma specimens. This could be due to paracrine secretion of tPA from
the surrounding stromal cells. Studies of tPA in the brain and in some cancer cells have
indicated that tPA has another role in addition to fibrinolysis. Intrestingly, tPA, like
uPA, also appears capable reversing PAI-1 cell detachment. To date, this has not,
however, prompted research into an association between tPA and cell adhesion. uPA is
known to be able to function without its receptor and tPA has been established to have
high intrinsic activity in its zymogen form and to efficiently catalyze plasminogen
activation in the presence of co-factors such as fibrin or other binding proteins. It is
therefore justified to assume that tPA via plasmin or itself, might have a role in normal
epithelial cells. In addition, future studies should investigate the regulation of tPA with
tumor progression. Two of plasminogen activators, uPA and tPA, appear to be
regulated in opposite ways in certain cancers.
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